Insulet (PODD) Aktie Kurs
Insulet Kurs
Omsætningen er vokset med 41,6 % om året de seneste 19 år til 2,71 Mrd. USD. Indtjening pr. aktie er vokset med 81,5 % om året de seneste 7 år. Insulets nettoavance ligger på 9,1 %, op fra 1,5 % for flere år siden. Analytikernes mediankursmål er 180,00 USD, hvilket er over den aktuelle kurs med 33,6 %. Af 33 analytikere anbefaler 20 køb — den samlede vurdering er Køb.
Insulet aktiekurs
Insulet aktie og aktieanalyse
Hyppigt stillede spørgsmål om Insulet-aktien
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 185,18 USD for Insulet-aktien (median: 180,00 USD), svarende til +37,4 % i forhold til seneste kurs. Konsensus bygger på 33 analytikervurderinger.
33 analytikere vurderer i øjeblikket Insulet-aktien: 20 anbefaler køb, 13 hold og 0 salg. For 2026 forventer analytikere, at Insulet genererer omsætning på 3,29 Mrd. USD og indtjening pr. aktie på 6,62 USD.
Omregnet til den aktuelle valutakurs handles Insulet-aktien til 120,28 EUR (134,77 USD).
Insulet-aktien (PODD) er noteret på 5 børser, herunder: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
forventet-omsætningen for Insulet er 3,29 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Insulet er 467,51 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Insulet er i øjeblikket 20,37. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Insulet-aktien.
Pris-til-salgs-forholdet (P/S) for Insulet er i øjeblikket 2,89. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Insulet-aktien.
AlleAktien-kvalitetsscore for Insulet er 6/10.
ISIN for Insulet er US45784P1012. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Insulet er A0MQX8. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Insulet er PODD. Tickersymbolet bruges til at handle Insulet-aktier på børsen.
Insulet aktie
Insulet Peer Group
Insulet Ticker
Insulet FIGI
Alle fundamentale data om Insulet i deep dive
Vores aktieanalyse af Insulet-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Insulet. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: